Novel b-cell epitopes of non-neutralizing antibodies in the receptor-binding domain of the S-protein of SARS-CoV-2 with differing effects on the severity of the course of COVID-19
- Autores: Matveev A.1, Pyankov O.2, Khlusevich Y.1, Tyazhelkova O.1, Emelyanova L.1, Timofeeva A.1, Shipovalov A.2, Chechushkov A.1, Zaitseva N.3
-
Afiliações:
- Federal State Public Scientific Institution “Institute of Chemical Biology and Fundamental Medicine”, Siberian Branch of the Russian Academy of Sciences
- State Research Center of Virology and Biotechnology “VECTOR”, Federal Service for the Oversight of Consumer Protection and Welfare
- FIC FTM
- Edição: Volume 88, Nº 9 (2023)
- Páginas: 1461-1472
- Seção: Articles
- URL: https://journals.rcsi.science/0320-9725/article/view/141481
- DOI: https://doi.org/10.31857/S0320972523090026
- EDN: https://elibrary.ru/WSPWAK
- ID: 141481
Citar
Resumo
Palavras-chave
Sobre autores
A. Matveev
Federal State Public Scientific Institution “Institute of Chemical Biology and Fundamental Medicine”, Siberian Branch of the Russian Academy of Sciences
Email: guterus@gmail.com
630090 Novosibirsk, Russia
O. Pyankov
State Research Center of Virology and Biotechnology “VECTOR”, Federal Service for the Oversight of Consumer Protection and Welfare630559 Koltsovo, Novosibirsk region, Russia
Y. Khlusevich
Federal State Public Scientific Institution “Institute of Chemical Biology and Fundamental Medicine”, Siberian Branch of the Russian Academy of Sciences630090 Novosibirsk, Russia
O. Tyazhelkova
Federal State Public Scientific Institution “Institute of Chemical Biology and Fundamental Medicine”, Siberian Branch of the Russian Academy of Sciences630090 Novosibirsk, Russia
L. Emelyanova
Federal State Public Scientific Institution “Institute of Chemical Biology and Fundamental Medicine”, Siberian Branch of the Russian Academy of Sciences630090 Novosibirsk, Russia
A. Timofeeva
Federal State Public Scientific Institution “Institute of Chemical Biology and Fundamental Medicine”, Siberian Branch of the Russian Academy of Sciences630090 Novosibirsk, Russia
A. Shipovalov
State Research Center of Virology and Biotechnology “VECTOR”, Federal Service for the Oversight of Consumer Protection and Welfare630559 Koltsovo, Novosibirsk region, Russia
A. Chechushkov
Federal State Public Scientific Institution “Institute of Chemical Biology and Fundamental Medicine”, Siberian Branch of the Russian Academy of Sciences630090 Novosibirsk, Russia
N. Zaitseva
FIC FTM630117 Novosibirsk, Russia
Bibliografia
- Kubiak, J. Z., and Kloc, M. (2023) Coronavirus Disease Pathophysiology: Biomarkers, Potential New Remedies, Comorbidities, Long COVID-19, Post Pandemic Epidemiological Surveillance, Int. J. Mol. Sci, 2023, 12236, doi: 10.3390/ijms241512236.
- Masters, P. S. (2006) The molecular biology of coronaviruses, Adv. Virus Res., 65, 193-292, doi: 10.1016/S0065-3527(06)66005-3.
- Jiang, S., Hillyer, C., Du, L. (2020) Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses, Trends Immunol., 41, 355-359, doi: 10.1016/j.it.2020.03.007.
- Maier, H. J., Bickerton, E., and Britton, P. (2015) Coronaviruses: methods and protocols, Methods in Molecular Biology, 1282, 1-282, doi: 10.1007/978-1-4939-2438-7.
- Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T., and Veesler, D. (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell, 181, 281-292.e6, doi: 10.1016/j.cell.2020.02.058.
- Guo, Y., Huang, L., Zhang, G., Yao, Y., Zhou, H., et al. (2021) A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes, Nat. Commun., 12, 2623, doi: 10.1038/s41467-021-22926-2.
- Sun, M., Liu, S., Wei, X., Wan, S., Huang, M., et al. (2021) Aptamer blocking strategy inhibits SARS-CoV-2 virus infection, Angew. Chem., 60, 10266-10272, doi: 10.1002/anie.202100225.
- Barh, D., Tiwari, S., Silva Andrade, B., Giovanetti, M., Almeida Costa, E., et al. (2020) Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain, F1000Res., 9, 576, doi: 10.12688/f1000research.24074.1.
- Chaouat, A. E., Achdout, H., Kol, I., Berhani, O., Roi, G., et al. (2021) SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection, PLoS Pathog., 17, e1010175, doi: 10.1371/journal.ppat.1010175.
- Nassar, M., Nso, N., Gonzalez, C., Lakhdar, S., Alshamam, M., et al. (2021) COVID-19 vaccine-induced myocarditis: case report with literature review, Diabetes Metab. Syndrome, 15, 102205, doi: 10.1016/j.dsx.2021.102205.
- Morgan, M. C., Atri, L., Harrell, S., Al-Jaroudi, W., Berman, A. (2022). COVID-19 vaccine-associated myocarditis, World J. Cardiol., 14, 382-391, doi: 10.4330/wjc.v14.i7.382.
- Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., et al. (2020) A human monoclonal antibody blocking SARS-CoV-2 infection, Nat Commun., 4, 2251, doi: 10.1038/s41467-020-16256-y.
- Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F., Sahi, V., Figueroa, A., Guo, X. V., Cerutti, G., Bimela, J., Gorman, J., Zhou, T., Chen, Z., Yuen, K. Y., Kwong, P. D., Sodroski, J. G., Yin, M. T., Sheng, Z., Huang, Y., Shapiro, L., and Ho, D. D. (2020) Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike, Nature, 584, 450-456, doi: 10.1038/s41586-020-2571-7.
- Deshpande, A., Harris, B. D., Martinez-Sobrido, L., Kobie, J. J., and Walter, M. R. (2021) Epitope classification and RBD binding properties of neutralizing antibodies against SARS-CoV-2 variants of concern, Front. Immunol., 12, 691715, doi: 10.3389/fimmu.2021.691715.
- Chen, Y., Zhao, X., Zhou, H., Zhu, H., Jiang, S., and Wang, P. (2023) Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses, Nat. Rev. Immunol., 23, 189-199, doi: 10.1038/s41577-022-00784-3.
- Shi, J., Zheng, J., Tai, W., Verma, A. K., Zhang, X., et al. (2022) A glycosylated RBD protein induces enhanced neutralizing antibodies against omicron and other variants with improved protection against SARS-CoV-2 infection, J. Virol., 96, e0011822, doi: 10.1128/jvi.00118-22.
- Timofeeva, A. M., Sedykh, S. E., Ermakov, E. A., Matveev, A. L., Odegova, E. I., et al. (2022) Natural IgG against S-protein and RBD of SARS-CoV-2 do not bind and hydrolyze DNA and are not autoimmune, Int. J. Mol. Sci., 23, 13681, doi: 10.3390/ijms232213681.
- Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C. L., et al. (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, 367, 1260-1263, doi: 10.1126/science.abb2507.
- Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem., 72, 248-254, doi: 10.1006/abio.1976.9999.
- Matveev, A. L., Krylov, V. B., Emelyanova, L., Solovev, A. S., Khlusevich, Y. A., et al. (2018) Novel mouse monoclonal antibodies specifically recognize Aspergillus fumigatus galactomannan, PLoS One, 13, e0193938, doi: 10.1371/journal.pone.0193938.
- Levanov, L. N., Matveev, L. E., Goncharova, E. P., Lebedev, L. R., Ryzhikov, A. B., et al. (2010) Chimeric antibodies against tick-borne encephalitis virus, Vaccine, 28, 5265-5271, doi: 10.1016/j.vaccine.2010.05.060.
- Borgoyakova, M. B., Karpenko, L. I., Rudometov, A. P., Shanshin, D. V., Isaeva, A. A., Nesmeyanova, V. S., et al. (2021) Immunogenic properties of the DNA construct encoding the receptor-binding domain of the SARS-CoV-2 spike protein, Mol. Biol., 55, 889-898, doi: 10.1134/S0026893321050046.
- Reed, L. J., and Muench, H. (1938) A simple method of estimating fifty percent endpoints, Am. J. Hyg., 27, 493-497, doi: 10.1093/oxfordjournals.aje.a118408.
- Khlusevich, Y. A., Matveev, A. L., Baykov, I. K., Bulychev, L. E., Bormotov, N. I., et al. (2018) Phage display antibodies against ectromelia virus that neutralize variola virus: selection and implementation for p35 neutralizing epitope mapping, Antivir. Res., 152, 18-25, doi: 10.1016/j.antiviral.2018.02.006.
- Matveev, A. L., Krylov, V. B., Khlusevich, Y. A., Baykov, I. K., Yashunsky, D. V., et al. (2019) Novel mouse monoclonal antibodies specifically recognizing β-(1-3)-D-glucan antigen, PLoS One, 14, 4, e0215535, doi: 10.1371/journal.pone.0215535.
- Yang, M., Li, J., Huang, Z., Li, H., Wang, Y., et al. (2021) Structural basis of a human neutralizing antibody specific to the SARS-CoV-2 spike protein receptor-binding domain, Microbiol. Spectr., 9, e01352-21, doi: 10.1128/Spectrum.01352-21.
- Yuan, M., Huang, D., Lee, C. D., Wu, N. C., Jackson, A. M., Zhu, X., Liu, H., Peng, L., van Gils, M. J., Sanders, R. W., Burton, D. R., Reincke, S. M., Prüss, H., Kreye, J., Nemazee, D., Ward, A. B., and Wilson, I. A. (2021) Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants, Science, 373, 818-823, doi: 10.1126/science.abh1139.
- Khlusevich, Y. A., Matveev, A. L., Emelyanova, L. A., Goncharova, E. P., Golosova, N. N., et al. (2022) New p35 (H3L) epitope involved in vaccinia virus neutralization and its deimmunization, Viruses, 14, 1224, doi: 10.3390/v14061224.
- Bahnan, W., Wrighton, S., Sundwall, M., Bläckberg, A., Larsson, O., et al. (2022) Spike-dependent opsonization indicates both dose-dependent inhibition of phagocytosis and that non-neutralizing antibodies can confer protection to SARS-CoV-2, Front. Immunol., 12, e808932, doi: 10.3389/fimmu.2021.808932.
![](/img/style/loading.gif)